Danielle Bucco | Authors

May 31, 2018

Patients with renal cell carcinoma have seen a change in standard of care as novel therapies and combinations are quickly approved, says Toni K. Choueiri, MD.

May 23, 2018

The frontline treatment of patients with ovarian cancer may potentially change in the near future, with targeted and immunotherapy strategies showing promising signals of activity.

May 08, 2018

While PARP inhibitors have demonstrated success in ovarian cancer previously, they are finally impacting the treatment paradigm for patients with BRCA-positive breast cancers, according to Nadine M. Tung, MD.

April 25, 2018

While relapsed/refractory mantle cell lymphoma (MCL) is considered an aggressive disease, new findings show patients may benefit from adding chimeric antigen receptor T-cell therapy to their treatment regimen. ZUMA-2, a currently ongoing trial, aims to understand the potential benefits with axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, for patients with relapsed/refractory MCL.

April 10, 2018

According to Neil E. Kay, MD, novel agents, such as ibrutinib (Imbruvica), venetoclax (Venclexta), idelalisib (Zydelig), and acalabrutinib (Calquence), are revolutionizing treatment for patients with chronic lymphocytic leukemia. However, the best way to sequence these agents to maximize the benefit to patients is still unclear.

March 13, 2018

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.